Crossref
Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study
AME Clinical Trials Review · 2026-06 · 4 · 23-23
DOI: 10.21037/actr-25-116 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Alessandra Merlini und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Merlini, A., & Bironzo, P. (2026). Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study. AME Clinical Trials Review, 4, 23-23. https://doi.org/10.21037/actr-25-116
Vancouver
Merlini A, Bironzo P. Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study. AME Clinical Trials Review. 2026;4:23-23. doi:10.21037/actr-25-116
BibTeX
@article{Merlini2026,
author = {Merlini, Alessandra and Bironzo, Paolo},
title = {Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {23--23},
doi = {10.21037/actr-25-116}
}
EUVIMED